SCHEMBL19435546

SCHEMBL19435546

COc1cc(F)c2cnsc2c1Br

nearest known ligand 0.32

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.32
CA2 P00918 3/20 0.32
CA4 P22748 3/20 0.32
CA6 P23280 3/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
NSD2 O96028 1/20 0.31
CASP6 P55212 1/20 0.31
XPO1 O14980 1/20 0.31
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31
ALDH1A1 P00352 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL911180 0.71 NQO1 (0.33) PDGFRBPDGFRAALDH1A1
SCHEMBL19435470 0.71 XPO1 (0.38) CA2CA4XPO1PDGFRBPDGFRA
SCHEMBL19435493 0.70 KIT (0.37) CA1CA2NSD2
SCHEMBL19435489 0.68 CYP19A1 (0.38) XPO1ALDH1A1L3MBTL1
SCHEMBL4801476 0.68 NQO2 (0.38) ALDH1A1L3MBTL1
SCHEMBL9678363 0.65 TUBB1 (0.40) CA1CA2CA4CA6ESR1
SCHEMBL28387502 0.65 TAAR1 (0.38) XPO1ALDH1A1
SCHEMBL20698169 0.62 TUBB1 (0.36) ALDH1A1L3MBTL1
SCHEMBL4799941 0.62 ALDH1A1 (0.38) ALDH1A1
SCHEMBL6070092 0.61 MAPT (0.38) CA2CA4ESR1ESR2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP disclosed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 CA1 1332/4885CA2 489/4885CA4 1544/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 CA1 1351/4885CA2 511/4885CA4 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.